COSCIENS Biopharma Inc. (CSCIF)
OTCMKTS
· Delayed Price · Currency is USD
2.600
-0.040 (-1.52%)
At close: Sep 17, 2025
COSCIENS Biopharma Employees
COSCIENS Biopharma had 40 employees as of December 31, 2024. The number of employees increased by 28 or 233.33% compared to the previous year.
Employees
40
Change
28
Growth
233.33%
Revenue / Employee
$236,050
Profits / Employee
-$471,050
Market Cap
8.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40 | 28 | 233.33% |
| Dec 31, 2020 | 12 | -44 | -78.57% |
| Dec 31, 2014 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Federal National Mortgage Association | 8,200 |
| Federal Home Loan Mortgage | 8,103 |
| Central Bancompany | 2,277 |
| Jingbo Technology | 154 |
| Wilson Bank Holding Company | 596 |
COSCIENS Biopharma News
- 4 weeks ago - COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 6 months ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire